Novo Nordisk is trading 3.08% down now at €39.35 after Deutsche Bank downgraded the shares from Hold to Sell on August 27, 2026.
- Analyst Emmanuel Papadakis cut the price target from 290 to 265 Danish kroner, citing mixed earlier-month results and uncertainty ahead of the company’s capital-markets day.
- China accepted Novo Nordisk’s oral Wegovy filing, but the downgrade outweighed the news as broader markets were mostly stronger.